Sarah Cannon Research Institute Presents Findings of Blood Cancer Clinical Trials at National Conference
December 10, 2011
NASHVILLE, TN, Dec. 10, 2011 – Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
“Our physicians are committed to bringing innovative new treatments to cancer patients and elevating SCRI’s reputation as a world leader in clinical research in the areas of leukemia, lymphoma and other hematologic malignancies,” said SCRI Chief Medical Officer and Executive Director, Drug Development Howard A. Burris III, M.D.
Ian W. Flinn, M.D., Ph.D., director, hematologic malignancies research and the Sarah Cannon Center for Blood Cancers, will present the preliminary result of a phase II trial of ofatumumab for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The session, titled, “CLL – Therapy, Excluding Transplantation: Poster III”, will be held December 12 from 6:00-8:00 p.m. PT.
Jesus G. Berdeja, M.D., director, myeloma research and senior investigator, hematologic malignancies will present data in oral and poster presentations at the meeting. The first will show findings of a phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma in an oral session called “Myeloma - Therapy, excluding Transplantation I” on Monday, December 12 at 11:30 a.m. PT. The second study, a phase II trial of combined bendamustine, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for high-dose chemotherapy: results of a planned interim safety analysis, will be presented in a poster session titled “Myeloma – Therapy, excluding Transplantation: Poster II” on Sunday, December 11, from 6:00-8:00 p.m. PT.
Drs. Flinn and Berdeja served as co-authors on 12 other abstracts that were accepted for presentation at the meeting. They include:
|
Presentation Title |
Presentation Details: |
|
Nilotinib Versus Imatinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 36-Month Follow-up |
Session: 632 - Chronic Myeloid Leukemia - Therapy: New First Line Options Date: Monday, December 12, 10:45am PT Co-author: Dr. Flinn |
|
Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase I Study of Ponatinib in Refractory Hematologic Malignancies |
Session: 632 - Chronic Myeloid Leukemia - Therapy: New Drugs, New Procedures Date: Monday, December 12, 3:00pm PT Co-author: Dr. Flinn |
|
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase IIIb UPFRONT Study |
Session: 653 - Myeloma - Therapy, excluding Transplantation I Date: Monday, December 12, 11:15am PT Co-author: Dr. Flinn |
|
The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Follow-up of a Phase Ib/II Study |
Session: 642 - CLL - Therapy, excluding Transplantation: Relapse treatment, novel agents and treatment related complications Date: Tuesday, December 13, 8:30am PT Co-author: Dr. Flinn |
|
Phase I Study of TRU-016, An Anti-CD37 SMIPTM Protein in Relapsed and/or Refractory NHL Patients
|
Session: 624 - Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I Date: Saturday, December 10, 5:30-7:30pm PT Co-author: Dr. Flinn |
|
A Phase I Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia |
Session: 642 - CLL - Therapy, excluding Transplantation: Poster I Saturday, December 10, 5:30-7:30pm PT Co-author: Dr. Flinn |
|
Patient-Reported Quality of Life in Elderly, Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase IIIb UPFRONT Study |
Session: 653 - Myeloma - Therapy, excluding Transplantation: Poster I Date: Saturday, December 10, 5:30-7:30pm PT Co-author: Dr. Flinn |
|
Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia |
Session: 901 - Health Services and Outcomes Research: Poster I Date: Saturday, December 10, 5:30-7:30pm PT Co-author: Dr. Flinn |
|
A Phase I Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma |
Session: 623 - Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Poster II Date: Sunday, December 11, 6:00-8:00pm PT Co-author: Dr. Flinn |
|
Patterns of Care for Patients with Chronic Lymphocytic Leukemia: The Connect® CLL Disease Registry |
Session: 642 - CLL - Therapy, excluding Transplantation: Poster II Date: Sunday, December 11, 6:00-8:00pm PT Co-author: Dr. Flinn |
|
Results From a Phase I Multicenter Trial of Alisertib (MLN8237) – An Investigational Aurora A Kinase Inhibitor – in Patients with Advanced Hematologic Malignancies |
Session: 604 - Molecular Pharmacology, Drug Resistance: Poster II Date: Sunday, December 11, 6:00-8:00pm PT Co-author: Dr. Berdeja |
|
Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes |
Session: 633 - Myelodysplastic Syndromes: Poster III Date: Monday, December 12, 6:00-8:00pm PT Co-author: Dr. Berdeja |
ASH’s annual meeting is the premier event in the hematology industry, attracting more than 20,000 hematologists and other health-care professionals from all 50 states and nearly 100 other countries.
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit us on sarahcannonresearch.com, or find us on Facebook and Twitter.
Twitter Facebook YouTube Linked In